Needham analyst Mike Matson lowered the firm’s price target on Conmed (CNMD) to $61 from $91 and keeps a Buy rating on the shares. The company’s Q1 revenue growth slowed to 3.8% from 6.0% in Q4 as Conmed continued to have supply chain challenges and had one less selling day, the analyst tells investors in a research note. Needham adds that it expects 2025 to be a transition year as Conmed addresses its supply chain issues with the help of an outside consultant.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNMD:
- Conmed’s Strong Q1 Performance and Raised Guidance Justify Buy Rating Despite Tariff Challenges
- Conmed price target lowered to $57 from $70 at Wells Fargo
- CONMED Corporation Reports Q1 2025 Financial Results
- Conmed reports Q1 EPS 95c, consensus 81c
- Conmed raises FY25 EPS view to $4.45-$4.60, consensus $4.34